October 25, 2022

Johnson & Johnson Vision Receives Approval in Canada for ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management

Abiliti™ Overnight lenses are the first and only orthokeratology lens approved for myopia control in Canada¹
Specifically designed to match a patient’s eye based on its unique corneal shape and prescription²
Lenses are worn overnight and typically eliminate the need to wear other vision correction during the day^3,4

JACKSONVILLE, FL – October 25, 2022 – Johnson & Johnson Vision,^‡ a global leader in eye health and part of Johnson & Johnson MedTech, ^§ received approval from Health Canada for ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management. These orthokeratology (ortho-k) lenses are worn overnight for the control of myopia and are specifically designed to match a patient’s eye based on its unique corneal shape and prescription to temporarily reshape the cornea.^1,3,4,5,6 This approval follows Health Canada’s approval of ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management in September 2021.

Myopia is sometimes called ‘nearsightedness’ but it is much more. It is a chronic and progressive disease that poses the biggest eye health threat of the 21st century.^7,8,9,10 Children under 12 who are diagnosed with myopia are at greater risk of developing high myopia which may lead to sight threatening disease later in life.¹¹ Additionally, half of the world’s population is projected to be myopic by 2050 with nearly one billion people expected to have high myopia.¹²

“Johnson & Johnson Vision is helping to address the dramatically increasing rates of myopia by bringing forward innovate products, services and solutions to help control the disease and give families a chance at better eye health in the future,” said Chandra Mickles, OD, MS, FAAO, FSLS, North America Professional Education Lead, Myopia, Johnson & Johnson Vision.^** “With Abiliti™ Overnight lenses and Abiliti™ 1-Day lenses, we are adding to our growing suite of Abiliti™ products to help change the trajectory of myopia.”

Clinical studies have shown Abiliti™ Overnight lenses are a successful option for controlling the progression of myopia.^13,14,15 The lenses are simple to prescribe by inputting the patient’s refraction, iris diameter and corneal topography data into the FitAbiliti™ software, which evaluates and recommends a lens with a first fit success rate of approximately 90%.^††,6 Abiliti™ Overnight lenses will be available in two different contact lens designs: ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management, and ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management for Astigmatism.²

Each annual purchase of an Abiliti™ product will provide a free comprehensive eye health exam to a child in need through Sight For Kids® – a joint program from Johnson & Johnson Vision^‡ and the not-for- profit Lions Clubs International Foundation (LCIF). Sight For Kids® is one of the largest-known, school- based eye health programs that mobilizes LCIF and eye care professionals to provide comprehensive eye health services in low-income schools around the world.

The Health Canada approval of Abiliti™ Overnight lenses stems from the collaboration of Johnson & Johnson Vision with Menicon to bring forward therapeutic contact lenses for myopia control under the Abiliti™ brand. Abiliti™ Overnight lenses are now available in select parts of Canada. Families and eye care professionals who want more information can visit www.seeyourabiliti.com.

###

About ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management

ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management are orthokeratology lenses approved by Health Canada for use in the control of myopia in non-diseased eyes when prescribed and managed by a qualified eye care professional. Abiliti™ Overnight lenses are worn overnight to temporarily reduce refractive error up to 4.00D (sphere product) and up to 5.00D and up to 3.50 of astigmatism (toric product), and subject to the eye care professional’s myopia control plan, may eliminate the need to wear contact lenses or glasses throughout the waking hours after lenses are removed. ^‡‡, ²

About Johnson & Johnson Vision^‡

At Johnson & Johnson Vision, part of Johnson & Johnson MedTech, we have a bold ambition: to change the trajectory of eye health around the world. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better and live better. Visit us at www.jjvision.com. Follow @JNJVision on Twitter and Johnson & Johnson Vision on LinkedIn.

About Johnson & Johnson MedTech^§

At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.

Important Safety Information for Contact Lens Wearers

ACUVUE® Abiliti™ Overnight Therapeutic Contact Lenses are available by prescription for use in the control of myopia. An eye care professional will determine whether these contact lenses are right for you. Although, rare, serious eye problems including vision loss and blindness can develop while wearing contact lenses. To help avoid these symptoms, follow the wear and replacement schedule and the lens care disinfection instructions provided by your eye care professional. Do not wear these contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, remove the lens and contact your eye care professional immediately. For more information on proper wear, care and safety, talk to your eye care professional and review the Patient Instruction Guide, call 1-877-337-3937, or visit www.seeyourabiliti.com.

ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management are available by prescription only for the correction of myopia (while the lenses are worn) and may slow the progression of myopia in children (7-12 years old). An eye care professional will determine whether these contact lenses are right for you or your child. Although extremely rare, serious eye problems including vision loss and blindness can develop while wearing contact lenses. To help avoid these symptoms, follow the wear and replacement schedule provided by your eye care professional. Do not wear these contact lenses if you or your child has an eye infection, or experiences eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, remove the lens and contact your eye care professional immediately. Due to the optical design of these lenses, under certain circumstances, some patients may experience visual symptoms. These lenses will provide vision correction while worn, but the vision quality may not be as clear as with conventional soft contact lenses. Patients should exercise extra care if performing potentially hazardous, vision demanding activities. For more information on proper wear, care and safety, talk to your eye care professional and review the Patient Instruction Guide, call 1-877-334-3937, or visit www.seeyourabiliti.com.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation

Reform Act of 1995 regarding ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Vision, any of the other Johnson & Johnson MedTech Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Johnson & Johnson Vision, the Johnson & Johnson MedTech Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

* As of September 19, 2022, based on publicly available resources
† Reducing refractive error up to 4.00D (sphere product) and up to 5.00D and up to 3.50D of astigmatism (toric product)
‡ Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
§ Johnson & Johnson MedTech comprises the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment.
** Chandra Mickles, OD, MS, FAAO, FSLS, is an employee of Johnson & Johnson Vision Care, Inc., with oversight of North America Professional Education for Myopia for the Vision Care organization.
†† Final lens fit is determined by the ECP – software is for decision support only.
‡‡ Results may vary by patient and prescription level.
1 Data on File 2022. Menicon Design History file
2 Data on File 2022. Instructions for Use (Canada)
3 Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, et al. Short-term changes in ocular biometry and refraction after discontinuation of long-term orthokeratology. Eye Contact Lens. 2014;40(2):84-90. doi: 10.1097/ICL.0000000000000014.
4 Cho P, Cheung SW. Discontinuation of orthokeratology on eyeball elongation (DOEE). Contact Lens Anterior Eye. 2017;40(2):82-87. doi: 10.1016/j.clae.2016.12.002.
5 Lau JK, Vincent SJ, Cheung SW, et al. The influence of orthokeratology compression factor on ocular higher-order aberrations. Clin Exp Optom. 2020;103(1):123-128. doi: 10.1111/cxo.12933.
6 Wan K, Lau JK, Cheung SW, et al. Refractive and corneal responses of young myopic children to short-term orthokeratology treatment with different compression factors. Contact Lens Anterior Eye. 2020;43(1):65-72. doi: 10.1016/j.clae.2019.10.134.
7 Flitcroft DI et al. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31(6):622-660.
8 Donovan L, Sankaridurg P, Ho A et al. Myopia progression rates in urban children wearing single-vision spectacles. OVS 2012;89(1):27-32.
9 Pärssinen O, Kauppinen M. Risk factors for high myopia: a 22-year follow-up study from childhood to adulthood. Acta Ophthalmologica. 2019;97(5):510-518.
10 Holy C, Kulkarni K, Brennan NA. Predicting Costs and Disability from the Myopia Epidemic – A Worldwide Economic and Social Model. Invest Ophthalmol Vis Sci.2019;60(9):5466-5466.
11 Hu Y, Ding X, Guo X, Chen Y, Zhang J, He M. Association of Age at Myopia Onset with Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort. Jama Ophthalmol. 2020;138(11):1129-1134. doi:10.1001/jamaophthalmol.2020.3451.
12 Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo K, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 to 2050. Ophthalmol. 2016;123(5):1036-1042. doi: 10.1016/j.ophtha.2016.01.006.
13 Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci [Internet]. 2012/09/13. 2012;53(11):7077–85.
14 Chen C, Cheung SW, Cho P. Myopia control using toric orthokeratology (TO-SEE study). Invest Ophthalmol Vis Sci [Internet]. 2013/09/05. 2013;54(10):6510–7.
15 Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Orthokeratology vs. spectacles: adverse events and discontinuations. Optom Vis Sci. 2012 Aug;89(8):1133-9.

PP2022ABL4026